Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shares jump after Spectris confirms KKR interest

(Sharecast News) - Shares in Spectris rallied on Monday after it rebuffed a takeover approach from US private equity giant KKR, fuelling hopes of a potential bidding war. The British manufacturer of high-tech scientific instruments is already in discussions with American buyout firm Advent International regarding a possible cash offer of £37.63 per share, or £4.4bn including debt.

But late on Friday, Spectris confirmed KKR had also approached it about a possible takeover.

It did not disclose financial details of KKR's preliminary and conditional cash offer. But it did confirm the approach was KKR's second, and that both had been rejected.

Shares in the FTSE 250 firm spiked as soon as trading resumed on Monday and by 1030 BST they had put on 6% at £33.46.

KKR now has until 1700 BST on 11 July to either announce a firm offer or walk away, a so-called put up or shut up deadline. KKR has yet to comment.

Spectris, which supplies highly-specialised sectors such as pharmaceuticals and semiconductors, said last Monday that it was minded to accept Advent's offer should it make a formal bid.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.